Viewing nowLyrica Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Allegrow Pharmaceuticals Co., Ltd.

MFDS item code 201904256 · Approved 2019.06.19 · Insurance code 656005230
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive therapy for partial seizures in patients with epilepsy, effective regardless of the presence of secondary general symptoms. Additionally, it helps in the treatment of fibromyalgia. It is employed to improve various neurological symptoms and conditions.
This medicine is administered orally, regardless of food, as pregabalin in two divided doses per day. Since this medicine is eliminated mainly by the kidneys, the dosage should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If needed, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is eliminated mainly by the kidneys in unchanged form. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. 72 ⅹ serum creatinine concentration (serum creatinine, mg/dl) *For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration method / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: The supplemental dose is the dose administered once as an additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children younger than 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so patients should consult a doctor immediately if they experience any changes in mood or behavior during treatment. Patients with hypersensitivity to this medication should not take it, and diabetic patients may need to adjust their diabetes management medications due to weight gain. If symptoms of angioedema occur, use should be discontinued immediately, and elderly patients should be cautious of dizziness or drowsiness to avoid falls or injuries. Transient visual disturbances or changes in vision may occur, and symptoms may improve upon discontinuation of the drug. When switching to this medication from existing antiepileptic drugs, it should be done cautiously as there is insufficient data regarding discontinuation of those medications. Discontinuation should not be abrupt, as withdrawal symptoms like insomnia, headaches, nausea, and anxiety may occur, thus it should be tapered gradually per a doctor's instructions. Due to the risk of drug abuse, patients with a history of mental illness or substance abuse should be closely monitored. Dose adjustments may be necessary for patients with impaired renal function, and caution should be exercised if administered to patients with heart failure. Concurrent use with opioid analgesics may exacerbate central nervous system depression, so caution is needed. Pregnant women are advised against using this medication during the early stages of pregnancy due to potential fetal impact, and women of childbearing potential should employ effective contraception. Dizziness or drowsiness may occur while taking this medication, so patients should refrain from engaging in dangerous activities like driving or operating machinery. Rarely, serious life-threatening skin reactions may occur; if any skin abnormalities appear, use should be immediately discontinued, and a physician should be notified. In case of overdose, symptoms such as confusion, drowsiness, and depression may arise, necessitating urgent medical treatment. Keep out of reach of children, and it is advisable to avoid transferring to another container.
Suicidal impulses, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual arousal disorder, agitation, mood swings, emotional decrease, emotional rise, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, loss of inhibition, apathy, ataxia, motor coordination disorders, balance disorders, memory loss, attention disorders, memory impairment, tremors, dysarthria, sensory abnormalities, sensory decrease, sedation, drowsiness syndrome, cognitive impairment, nystagmus, speech disorders, fasciculations, diminished reflexes, motor abnormalities, psychomotor agitation, position-induced dizziness, hypersensitivity, burning sensation, action tremor, syncope, confusion, bradykinesia, olfactory abnormalities, taste loss, writing difficulties, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, eye swelling, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, during vibration, changes in depth perception of the visual field, strabismus, brightness of the visual field, dizziness, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux, oral sensory decrease, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle spasms, joint pain, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle cramps, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, sensory disturbances, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, agitation, restlessness, seizure aggravation, angioedema, allergic reactions, anaphylactic-like symptoms, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to prevent air or moisture from entering. It is advisable to maintain the storage temperature between 15 and 30 degrees Celsius. This helps to preserve the effectiveness of the medication.
A hard capsule with a reddish-brown upper part and a white lower part containing white or pale yellow powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Allegrow Pharmaceuticals Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.